Literature DB >> 19161423

Th17 cytokines and mucosal immunity.

Patricia J Dubin1, Jay K Kolls.   

Abstract

The T-helper 17 (Th17) lineage is a recently described subset of memory T cells that is characterized by its CD4(+) status and its ability to make a constellation of cytokines including interleukin-17A (IL-17A), IL-17F, IL-22, and, in humans, IL-26. Although most extensively described in the autoimmunity literature, there is growing evidence that the Th17 lineage plays a significant role in mediating host mucosal immunity to a number of pulmonary pathogens. This review highlights our current understanding of the role of the Th17 lineage and Th17 cytokines in mediating mucosal immunity to both pulmonary and gastrointestinal pathogens. While we have the strongest evidence that the Th17 lineage is centrally involved in mediating the host response to Gram-negative extracellular pulmonary pathogens, this literature is rapidly evolving and demonstrates a central role for Th17 cytokines both in primary infection and in recall responses seen in vaccine studies. In this review, we summarize the current state of this literature and present possible applications of Th17-targeted immunotherapy in the treatment and prevention of infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19161423     DOI: 10.1111/j.1600-065X.2008.00703.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  83 in total

1.  The E3 ubiquitin ligase adaptor Ndfip1 regulates Th17 differentiation by limiting the production of proinflammatory cytokines.

Authors:  Hilda E Ramon; Allison M Beal; Yuhong Liu; George Scott Worthen; Paula M Oliver
Journal:  J Immunol       Date:  2012-03-07       Impact factor: 5.422

2.  Key Concepts in the Early Immunology of HIV-1 Infection.

Authors:  Basile Siewe; Alan Landay
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 3.  Deciphering the role of Th17 cells in human disease.

Authors:  Cailin Moira Wilke; Keith Bishop; David Fox; Weiping Zou
Journal:  Trends Immunol       Date:  2011-09-28       Impact factor: 16.687

Review 4.  Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

Authors:  Hsing-Chuan Tsai; Reen Wu
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

5.  Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis.

Authors:  Leon P McLean; Raymond K Cross; Terez Shea-Donohue
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

6.  Boosting the IL-22 response using flagellin prevents bacterial infection in cigarette smoke-exposed mice.

Authors:  B Koné; M Pérez-Cruz; R Porte; F Hennegrave; C Carnoy; P Gosset; F Trottein; J-C Sirard; M Pichavant; P Gosset
Journal:  Clin Exp Immunol       Date:  2020-05-17       Impact factor: 4.330

Review 7.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

8.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection.

Authors:  Kelsey E Sivick; Matthew A Schaller; Sara N Smith; Harry L T Mobley
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

10.  Combined administration of anti-IL-13 and anti-IL-17A at individually sub-therapeutic doses limits asthma-like symptoms in a mouse model of Th2/Th17 high asthma.

Authors:  Dasom Kim; Jaclyn W McAlees; Lindsay J Bischoff; Davinder Kaur; Lauren K Houshel; Jerilyn Gray; Julie Hargis; Xenia Davis; Paul L Dudas; Hitesh Deshmukh; Ian P Lewkowich
Journal:  Clin Exp Allergy       Date:  2018-11-29       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.